Skip to main content
SpringerLink
Log in

Novartis has announced that the final National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Novartis Pharmaceuticals UK Ltd.Final NICE Guidance Recommends Lucentis(R) (Ranibizumab) for wet AMD. Media Release: 27 Aug 2008. Available from: URL: http://www.novartis.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novartis has announced that the final National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Guidance. Pharmacoecon. Outcomes News 561, 10 (2008). https://doi.org/10.2165/00151234-200805610-00027

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805610-00027

Keywords

Search

Navigation